ニュース

Moderna (MRNA) is back in focus after Phase 3 data showed its mRNA flu vaccine outperformed standard shots in older adults, while separate hantavirus research tied to a cruise ship outbreak added further attention. See our latest analysis for Moderna. The latest flu and hantavirus updates come after a powerful run, with the stock showing a 58.91% year-to-date share price return and a very large 1-year total shareholder return. However, longer-term total shareholder returns over 3 and 5 years...

Investing.com -- Moderna Inc (NASDAQ:MRNA) shares rallied 13% over a multi-day period following reports of a localized Hantavirus outbreak aboard the cruise vessel MV Hondius.

Salesforce (NYSE:CRM) is rolling out new agentic AI deployments across core enterprise workflows. The company has launched Agentforce Contact Center with Ribbon Communications and AI-driven communications integrations at scale. Salesforce has partnered with Moderna to support global operations through Agentforce Life Sciences. The company has also introduced new e-signature integrations with Syncfusion to extend workflow coverage. These moves put Salesforce's AI platform directly into front...

Salesforce Inc. (NYSE:CRM) is one of the cheap stocks to buy for the next 10 years. On April 28, Salesforce and Moderna announced a new partnership to unify the biotech company’s global commercial operations through Agentforce Life Sciences. This collaboration aims to create a single, connected platform that integrates data from sources like SAP and […]

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 10.2% in the afternoon session after the company published positive Phase 3 clinical trial results for its seasonal flu vaccine candidate, mRNA-1010, and announced positive Phase 1 data for its hantavirus vaccine.

These 3 Covid-era stocks set up a 2026 comeback as hantavirus revives the pandemic trade and lifts one player 36% off May lows.

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

Evercore ISI analysts said in a note they “see no meaningful revenue opportunity” for Moderna in hantaviruses.

Moderna’s first quarter was marked by a sharp increase in revenue, driven by the fulfillment of large international contracts, particularly through a strategic partnership in the United Kingdom. Management attributed the strong year-over-year growth to international demand for its COVID vaccine products, with CEO Stéphane Bancel noting, “We grew year-over-year revenues significantly to $0.4 billion, driven primarily by execution of our long-term strategic partnership in the U.K.” Despite these g

On May 11, 2026, AI and chip stocks fueled fresh records as surging oil and valuation warnings tested nerves.

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.19%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.29%. June E-mini S&P futures (ESM26 ) rose +0.18%, and June E-mini Nasdaq futures...

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

After facing pressure from the summer of 2021 through the end of 2025, Moderna shares have staged an impressive comeback, rallying roughly 50% from their recent lows as investors return their focus to the biotech sector. The rally also received support following reports of a U.S. national testing positive for Hantavirus, as the company disclosed it is exploring an “early-stage and ongoing” treatment program targeting the disease. With those catalysts, let’s examine the technical setup on the daily and monthly charts.

Today, May 11, 2026, AI chip leaders helped steady major U.S. indexes at midday as the Strait of Hormuz remains largely closed.

The three major US stock indexes were up slightly in late-morning trading Monday after President Don

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares continued to extend recent gains on Monday as investors welcomed reports that the company is researching a hantavirus vaccine and advancing early-stage work in the area. Shares of Moderna have added more than 16% in the last five days, trading hands...

Moderna shares are rallying following a report the company is researching a hantavirus vaccine.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr

Moderna rallies 7% on hopes of hantavirus research.

President rejects Iran’s response, Warsh’s favored inflation measure, airlines are raising bag fees, and more news to start your day.

Moderna jumps after the U.S. health department says a passenger on a repatriation flight tested mildly positive for hantavirus. Moderna says it’s working on an ‘early-stage and ongoing’ treatment for hantavirus.

↗️ Moderna (MRNA): Shares jumped 8% premarket after the biomedical company told media outlets that it has been researching vaccines to protect against hantaviruses since before a recent cruise-ship outbreak.

The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.

CoreWeave drops after missing analysts’ earnings target, while Trade Desk plummets on weak revenue guidance.